Replies to post #68601 on Biotech Values

[DewDiligence]

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program is in phase-3 or beyond and is non-partnered.
b) Company does not have enough cash to bring the product to market.

Edits: DYAX, Pharming.

 
  Stock    Product          Stage                   Comments    
  -----    ---------------  ---------------------   -----------------------------    
  BPAX     Libigel          Phase 3 ~2010 Submit    Adequate Safety?    
  CHTP     Droxidopa        Pivotal Phase III       Orthostatic hypotension.  Results expected 02/09. 
  DYAX     DX-88 for HAE    BLA filed 9/24/08       (CABG indication partnered w CBST) 
  EPIX     Vasovist         PDUFA 12/30/08          FDA initially rejected saying 2 more studies needed. Looking to sell outright on approval. 
  GNVC     TNFerade         Pivotal Phase III       Pancreatic cancer   
  JAV      Dyloject         Phase III               Approved in UK.  Post operative Pain (injectable)  
  JAV      Ketamine         Phase III               Acute moderate-to-severe pain (intranasal)  
  NTII     Viprinex         Phase 3                 Interim analysis January '09.  Stroke Drug, high chance of failure.    
  OXGN     Zybrestat        Phase 3                 Anaplastic thyroid cancer 
  Pharming Rhucin           Pre-BLA                 Rejected in EU 
  RPRX     Proellex         Phase 3                 Uterine fibroids

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.